June 14, 2019
by Allison Gatlin

Phillip Gutis didn’t expect biotech companies Biogen (BIIB) and Eisai to cure his Alzheimer’s disease. But the former New York Times reporter did see his participation in a clinical study of the experimental drug, aducanumab, as a step toward finding an Alzheimer’s treatment….

Cortexyme (CRTX), is making a case for the inflammation theory. CEO Casey Lynch says an inflammatory bacteria could be the culprit behind Alzheimer’s disease. Cortexyme went public this year, trading for the first time in May…

Read more here